CATTRINI, CARLO
 Distribuzione geografica
Continente #
EU - Europa 2.322
Totale 2.322
Nazione #
IT - Italia 2.322
Totale 2.322
Città #
Genova 1.557
Genoa 365
Rapallo 337
Vado Ligure 61
Bordighera 2
Totale 2.322
Nome #
Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome 152
Androgen-deprivation therapy is more than palliation in oligometastatic prostate cancer 127
A hnRNP K–AR-related signature reflects progression toward castration-resistant prostate cancer 125
Cisplatin (C)-paclitaxel (P) chemotherapy (CT) regimen with concurrent radiotherapy (RT) in local advanced (LACC) or recurrent (LRCC) cervical cancer: 14 year-results of a phase II study 116
CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials 116
Prognostic variables in localized small cell neuroendocrine carcinoma of the bladder: A population-based study 116
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer 108
Bone metastases from prostate cancer: hormonal therapy 107
Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: A mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes 107
Targeting androgen-independent pathways: new chances for patients with prostate cancer? 103
Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients 101
Genitourinary tumours in the targeted therapies era: New advances in clinical practice and future perspectives 92
Immunotherapy for genitourinary cancer: State of the art and new perspectives 91
A large SEER- based study of survival trends in patients with de novo metastatic prostate cancer 84
To switch or not to switch? A real-life experience using dexamethasone in combination with abiraterone 82
Atezolizumab and bladder cancer: facing a complex disease 79
Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study 79
Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes 74
Lipidomic profiling in patients with metastatic castration-resistant prostate cancer (mCRPC) 70
Reduced dose of cabazitaxel in metastatic castration-resistant prostate cancer: from PROSELICA trial to the real life: A single institution experience 68
EFFICACY AND SAFETY OF SUNITINIB AND EVEROLIMUS AS FRONTLINE TREATMENT FOR NON-CC-RCC: A POOLED-ANALYSIS FROM RANDOMIZED TRIALS 63
Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer 53
Integrative Analysis of Periostin in Primary and Advanced Prostate Cancer 50
BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications 50
Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer 48
Combination therapy in metastatic renal cell carcinoma: Back to the future? 47
Real-world survival improvements in patients with newly diagnosed metastatic prostate cancer treated in the United States 46
Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study 41
null 40
Medical Liability in Cancer Care During COVID-19 Pandemic: Heroes or Guilty? 10
Totale 2.445
Categoria #
all - tutte 8.700
article - articoli 8.230
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 304
Totale 17.234


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020678 0 0 16 40 108 113 98 54 63 98 72 16
2020/2021369 16 42 20 63 38 32 6 32 18 50 23 29
2021/2022344 15 10 16 30 16 40 7 85 25 35 25 40
2022/2023388 28 47 3 37 79 55 0 30 50 7 47 5
2023/2024306 10 63 8 43 10 55 12 8 10 16 11 60
2024/202577 30 47 0 0 0 0 0 0 0 0 0 0
Totale 2.445